

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213

Status	RECRUITING
Phase	Phase 3
Sponsor	ADARx Pharmaceuticals, Inc.
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (4)

- Age ≥18 years at the time of signing informed consent.
- Have a documented diagnosis of HAE-1/HAE-2 (Type I or II)
- Experience e1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or e2 Investigator-confirmed HAE attacks in 8 weeks of Screening
- Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)

Exclusion (9)

- Concurrent diagnosis of another form of recurrent angioedema (such as acquired angioedema, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or recurrent angioedema associated with urticaria).
 - Any clinically significant renal disease
 - Any clinically significant hepatic disease
 - Have used any of the following for long-term prevention of HAE attacks:
 - C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.
- ... and 4 more (see full listing online)

Locations (14 total)

ADARx Clinical Site, Little Rock, Arkansas, United States
ADARx Clinical Site, Walnut Creek, California, United States
ADARx Clinical Site, Wheaton, Maryland, United States
... and 11 more locations